Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Aug;39(8):3857-3861.
doi: 10.1007/s12325-022-02213-2. Epub 2022 Jun 22.

Letter to the Editor Regarding "Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab"

Luigino Calzetta  1 , Paola Rogliani  2
Affiliations
Comment

Letter to the Editor Regarding "Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab"

Luigino Calzetta et al. Adv Ther. 2022 Aug.
No abstract available

Keywords: Benralizumab; Biologic therapy; CALIMA; Clinical remission; NNT; Oral corticosteroids; Post hoc analysis; SIROCCO; Severe asthma; ZONDA.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Fisher’s exact test comparing the number of severe asthmatic patients treated for 12 months with benralizumab 30 mg Q8W or placebo achieving the clinical remission according to the four-item composite definition proposed by Menzies-Gow et al. [1] (zero exacerbations and zero OCS use and ACQ-6 ≤ 0.75 and pre-BD FEV1 increase ≥ 100 mL). The analysis was performed on the overall population from SIROCCO [2] and CALIMA [3] studies (a) and in subgroup populations with blood eosinophil count ≥ 150 cells/μL (b) and ≥ 300 cells/μL (c). **P < 0.01 and ***P < 0.001. ACQ Asthma Control Questionnaire, BD bronchodilator, FEV1 forced expiratory volume in 1 s, OCS oral corticosteroids, Q8W every 8 weeks, first three doses 4 weeks apart
See this image and copyright information in PMC

Comment in

Comment on

References

    1. Menzies-Gow A, Hoyte FL, Price DB, et al. Clinical remission in severe asthma: a pooled post hoc analysis of the patient journey with benralizumab. Adv Ther. 2022 doi: 10.1007/S12325-022-02098-1. - DOI - PMC - PubMed
    1. Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016 doi: 10.1016/S0140-6736(16)31324-1. - DOI - PubMed
    1. FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128–2141. doi: 10.1016/S0140-6736(16)31322-8. - DOI - PubMed
    1. Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448–2458. doi: 10.1056/nejmoa1703501. - DOI - PubMed
    1. Menzies-Gow A, Bafadhel M, Busse WW, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020 doi: 10.1016/j.jaci.2019.12.006. - DOI - PubMed

MeSH terms